View Older Stories View More Recent Stories
-
Abbott (ABT) Raises Quarterly Dividend 6.8% to $0.63; 2% Yield
-
Benchmark Reiterates Buy Rating on Abbott Labs (ABT) Following Deal to Acquire Exact Sciences (EXAS)
-
UBS Reiterates Buy Rating on Abbott Labs (ABT): Modelling ~6% Dx growth TOT in 2026
-
Exact Sciences stock jumps after Abbott confirms acquisition
-
BTIG Reiterates Exact Sciences (EXAS) at Buy, 'tie up between ABT and EXAS makes sense'
-
Wolfe Research Reiterates Peerperform Rating on Abbott Labs (ABT)
-
Exact Sciences (EXAS) resumes trading, up 28%
-
Abbott reportedly nearing deal for Exact Sciences
-
Make sure you own this high-quality MedTech stock: RBC
-
Abbott Labs (ABT) PT Raised to $158 at UBS
-
UBS Reiterates Buy Rating on Abbott Labs (ABT), Highlights Buying Opportunity
-
Benchmark Reiterates Buy Rating on Abbott Labs (ABT), Following In-Line Q3 Results
-
RBC Capital Reiterates Outperform Rating on Abbott Labs (ABT), 'dips create opportunity'
-
Abbott Labs (ABT) PT Raised to $150 at Bernstein SocGen Group
-
Abbott Labs (ABT) PT Raised to $146 at Wells Fargo
-
Abbott Labs (ABT) PT Raised to $146 at Jefferies
-
Abbott (ABT) Reports In-Line Q3 EPS, Misses on Revenue; Offers FY25 EPS Guidance
-
Abbott (ABT) October 133 straddle priced into quarter results
-
Raymond James expects modest upside for this MedTech stock in Q3 results
-
Abbott (NYSE: ABT) call put ratio 1.2 calls to 1 put into quarter results
-
Benchmark Starts Abbott Labs (ABT) at Buy
-
Abbott Labs (ABT) 'One of Our Highest Conviction Calls' - UBS
-
UBS on why it's still not ready to push the buy button on pharma stocks
-
Here are the October additions to Goldman's 'U.S. Conviction List - Directors' Cut
-
Goldman Updates US Monthly Directors' Cut Conviction List, Fours Adds and Three Removals
-
Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'
-
UBS Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) Declares $0.59 Quarterly Dividend; 1.8% Yield
-
Piper Sandler on calls with diabetes clinicians
-
Piper Sandler: 'Abbott Labs (ABT) Remains Our Favorite Large-Cap Name'
-
This MedTech stock is 'a strong buy under $500': Bernstein
-
Gordon Haskett Comments Positively on Abbott (ABT)
-
UBS Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) 2500 contracts of July 127 calls trade, share price up 3.2%
-
Abbott Labs (ABT) PT Lowered to $155 at Citi
-
Abbott upgraded after post-earnings selloff, hardware drag seen temporary
-
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott Labs (ABT) PT Lowered to $135 at Mizuho
-
Jefferies Upgrades Abbott Labs (ABT) to Buy
-
Abbott Labs (ABT) PT Lowered to $145 at BTIG
-
Abbott Labs (ABT) PT Lowered to $140 at Evercore ISI
-
Goldman Sachs Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY25 EPS Guidance
-
Abbott (ABT) option IV bid into quarter results
-
Abbott Labs (ABT) PT Raised at RBC Capital Following Recent Stock Performance
-
Piper Sandler Reiterates Overweight Rating on Abbott Labs (ABT)
-
TD Cowen Expects a 'Good 2Q' for Abbott Labs (ABT)
-
Oppenheimer Reiterates Outperform Rating on Abbott Labs (ABT)
-
Piper Sandler's Key MedTech Takeaways From ADA 2025
-
Oppenheimer on Abbott Labs (ABT): 'we have become incrementally bullish'

